Timothy A. Yap, MBBS, PhD, FRCP, presented data from the MYTHIC trial, demonstrating a 60% ORR at the RP2D in patients with CCNE1-amplified PROC.
Timothy A. Yap, MBBS, PhD, FRCP
Advertisement
Articles by Timothy A. Yap, MBBS, PhD, FRCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
2
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
3
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)
4
What is the Future of TIL Therapy in Metastatic Melanoma?
5